FAKnostics is a dynamic pharmaceutical and diagnostics company, developing next generation drugs that inhibit tumor metastasis and survival. There are no current drugs which effectively block tumor metastasis. Our team was the first to discover FAK, a protein found in 60-80% of all metastatic cancers. We have developed a unique therapeutic approach and significant intellectual property around targeting a specific region of FAK called the FAK scaffold. Our FAK inhibitors have shown promising effects in melanoma and pancreatic cancer, but also in fibrotic diseases.
Our team has more than 35 years of FAK research leadership and therapeutic development, with core competencies in pharmacology and drug discovery, especially structure-based drug design, peptide chemistry, and computational drug discovery. Over the last 4 years, we have developed a focus on structure-based drug design to complement and extend our cancer biology capabilities. We continue the development of FAK-related drugs to provide new therapies for cancers, fibrosis, and other critically important diseases that lack effective treatment options.
Our team has more than 35 years of FAK research leadership and therapeutic development, with core competencies in pharmacology and drug discovery, especially structure-based drug design, peptide chemistry, and computational drug discovery. Over the last 4 years, we have developed a focus on structure-based drug design to complement and extend our cancer biology capabilities. We continue the development of FAK-related drugs to provide new therapies for cancers, fibrosis, and other critically important diseases that lack effective treatment options.
Speaker
